Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets

Behavioural Brain Research

Volumn 249, Issue , 2013, Pages 109-115

  Nakako, Tomokazu ^a   Murai, Takeshi ^a   Ikejiri, Masaru ^a   Ishiyama, Takeo ^a   Taiji, Mutsuo ^a   Ikeda, Kazuhito ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

CANTAB; Dopamine receptor D1; Ketamine; Marmoset; Schizophrenia; Spatial working memory

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALLITRICHINAE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; GAIT DISORDER; KETAMINE INDUCED SPATIAL WORKING MEMORY DYSFUNCTION; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; WORKING MEMORY;

ANIMALS; BENZAZEPINES; CALLITHRIX; DOPAMINE AGONISTS; KETAMINE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; RECEPTORS, DOPAMINE D1; SPATIAL BEHAVIOR;

EID: 84878091992     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.04.012     Document Type: Article

References (35)

1. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophrenia Bulletin 2000, 26:119-136.
2. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatric Clinics of North America 2003, 26:25-40.
3. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004, 56:301-307.
4. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry 2004, 65:361-372.
5. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research 2007, 184:31-38.
6. Mutlu O., Ulak G., Celikyurt I.K., Akar F.Y., Erden F., Tanyeri P. Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice. Pharmacology Biochemistry and Behavior 2011, 99:557-565.
7. Brown V.J., Bowman E.M. Rodent models of prefrontal cortical function. Trends in Neurosciences 2002, 25:340-343.
8. Uylings H.B., Groenewegen H.J., Kolb B. Do rats have a prefrontal cortex?. Behavioural Brain Research 2003, 146:3-17.
9. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991, 148:1301-1308.
10. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51:199-214.
11. Adler C.M., Goldberg T.E., Malhotra A.K., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biological Psychiatry 1998, 43:811-816.
12. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cerebral Cortex 2000, 10:1078-1092.
13. Mendrek A., Laurens K.R., Kiehl K.A., Ngan E.T., Stip E., Liddle P.F. Changes in distributed neural circuitry function in patients with first-episode schizophrenia. British Journal of Psychiatry 2004, 185:205-214.
14. Buffalo E.A., Gillam M.P., Allen R.R., Paule M.G. Acute behavioral effects of MK-801 in rhesus monkeys: assessment using an operant test battery. Pharmacology Biochemistry and Behavior 1994, 48:935-940.
15. Buccafusco J.J., Terry A.V. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochemical Pharmacology 2009, 78:852-862.
16. Elsworth J.D., Groman S.M., Jentsch J.D., Valles R., Shahid M., Wong E., et al. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 2012, 62:1442-1452.
17. Roberts B.M., Seymour P.A., Schmidt C.J., Williams G.V., Castner S.A. Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology 2010, 210:407-418.
18. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacology & Therapeutics 2010, 128:419-432.
19. Levaux M.N., Potvin S., Sepehry A.A., Sablier J., Mendrek A., Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry 2007, 22:104-115.
20. Hutton S.B., Huddy V., Barnes T.R., Robbins T.W., Crawford T.J., Kennard C., et al. The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia. Biological Psychiatry 2004, 56:553-559.
21. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2003, 174:3-16.
22. Buchanan R.W., Freedman R., Javitt D.C., Abi-Dargham A., Lieberman J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophrenia Bulletin 2007, 33:1120-1130.
23. Takahashi H., Yamada M., Suhara T. Functional significance of central D1 receptors in cognition: beyond working memory. Journal of Cerebral Blood Flow and Metabolism 2012, 32:1248-1258.
24. Pouget P., Wattiez N., Rivaud-Péchoux S., Gaymard B. Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. Psychopharmacology 2010, 209:313-318.
25. Owen A.M., Downes J.J., Sahakian B.J., Polkey C.E., Robbins T.W. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990, 28:1021-1034.
26. Owen A.M., Evans A.C., Petrides M. Evidence for a two-stage model of spatial working memory processing within the lateral frontal cortex: a positron emission tomography study. Cerebral Cortex 1996, 6:31-38.
27. Manes F., Sahakian B., Clark L., Rogers R., Antoun N., Aitken M., et al. Decision-making processes following damage to the prefrontal cortex. Brain 2002, 125:624-639.
28. Honey R.A., Turner D.C., Honey G.D., Sharar S.R., Kumaran D., Pomarol-Clotet E., et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 2003, 28:2037-2044.
29. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Molecular Pharmacology 2010, 77:317-326.
30. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 1997, 17:2921-2927.
31. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
32. Lewis D.A., Volk D.W., Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 2004, 174:143-150.
33. Paspalas C.D., Goldman-Rakic P.S. Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. Journal of Neuroscience 2005, 25:1260-1267.
34. Gao W.J., Krimer L.S., Goldman-Rakic P.S. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:295-300.
35. Seamans J.K., Durstewitz D., Christie B.R., Stevens C.F., Sejnowski T.J. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:301-306.